Key Updates in the Treatment of ES-SCLC

EP: 1.Expert Insights on Recent Advancements in LS-SCLC

Now Viewing

EP: 2.Key Updates in the Treatment of ES-SCLC

EP: 3.Expert Perspectives on Tarlatamab in ES-SCLC

EP: 4.Looking Ahead in SCLC: ADCs and Other Novel Agents

EP: 5.Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP: 6.Personalizing Adjuvant Targeted Therapy in Early-Stage NSCLC

EP: 7.New Targeted Approaches in Unresectable Early-Stage NSCL

EP: 8.Navigating New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

EP: 9.Expert Insights for Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP: 10.Latest Advances in the Management of Advanced NSCLC with ALK or ROS1 Mutations

EP: 11.Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

EP: 12.Tailoring Immunotherapy Strategies for Advanced NSCLC

Video content above is prompted by the following:

• What are your perceptions on recent retrospective real-world data comparing atezolizumab and durvalumab, and how do you incorporate these findings into your treatment decision making in patients with ES-NSCLC?
• Briefly discuss the role of lurbinectedin in the second-line treatment setting. How are you incorporating lurbinectedin into your treatment approach, and what is the potential role of novel lurbinectedin-based combination strategies?